CBG Atlas

Safety & reporting
Hub · propyl series

Varin cannabinoids

What are varin cannabinoids?

The short answer

Varin cannabinoids are the “propyl” series: their side chain runs three carbons long, where the usual cannabinoids carry five. That shorter chain defines the group and gives the names their “-varin” ending (“-varinic acid” for the acids). The chemistry is established; the pharmacology is mostly still being catalogued, so a varin’s behaviour can’t be read off its five-carbon counterpart.

Two carbons sounds like a rounding error. The common cannabinoids (CBG, CBD, THC) carry a pentyl (five-carbon) side chain; the varins carry a propyl (three-carbon) one and come from a separate acid line in the plant. Structurally, the chain is the whole difference, and it can still change how a molecule behaves, which is why each varin has to be studied in its own right.

The varins: identities established, pharmacology still being catalogued

Tetrahydrocannabivarin (THCV)

THC’s propyl analog. Lab studies report receptor activity that departs from THC’s; effects in people are not established.

Cannabidivarin (CBDV)

CBD’s propyl analog, and a varin that has actually been tested in people. The result: a completed Phase 2 randomised trial in focal seizures finished level with placebo.

To see what a varin is being measured against, go to its five-carbon (pentyl) counterpart among the minor cannabinoids; its acid or neutral partner sits under the cannabinoid acids.

The minor cannabinoids · The cannabinoid acids · How we grade evidence

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →